iShares iBonds 2036年12月期公债ETF IBTR 深 沪
等待开盘 05-21 09:30:00 美东时间
24.59
+0.184
+0.76%
华盛通- 最 高24.59
- 今 开24.49
- 成交量 5787股
- 最 低 24.43
- 昨 收 24.4057
- 总市值 491.80万
- 52周最高 25.161
- 市盈率 静 --
- 换手率 2.89%
- 52周最低 24.39
- 委 比 41.18%
- 总股本 20.00万
- 历史最高 25.161
- 量 比 1.58
- 振 幅 0.66%
- 历史最低 24.39
- 每 手 1
- 风险率 0.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nuvation Bio Reveals IBTROZI Showed Highly Durable Responses in Longer-Term Follow-Up Data From Pivotal Studies Presented At AACR 2026; IBTROZI Also Demonstrated A High Overall Response Rate In TKI-Naïve Patients At 89.8%; Preclinical Data Presented At AACR Showed Taletrectinib's Potential For Suppressing TrkB-mediated Lung Cancer Cell Migration
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up data from the
04-22 06:04
Nuvation Bio, Eisai application for taletrectinib for NSCLC accepted by EMA
The European Medicines Agency has accepted a Marketing Authorisation Application filed by Nuvation Bio (NUVB) and Eisai (ESALF)(ESAIY) for taletrectinib to treat non-small cell lung cancer. The applic...
03-27 05:26
